Immunohistochemistry (IHC) Market Archives

Growing burden of chronic & infectious diseases such as cancer; rapid growth in geriatric population across the globe; technological advancements in IHC solutions in terms of diagnostic accuracy, AI-integration, & multiplexing capability; and increasing number of research activities are some of the key factors driving the IHC market. The market is marked by the presence of key players such as Thermo Fisher Scientific, Inc. (US); F. Hoffmann-La Roche Ltd. (Switzerland); Merck KGaA (Germany); Bio-Rad Laboratories, Inc. (US); Danaher Corporation (US); PerkinElmer, Inc. (US); Becton, Dickinson and Company (US); and others. Immunohistochemistry (IHC) is a technique used in biological research and diagnostics to visualize the presence, localization, and abundance of specific proteins within tissue samples. IHC is an invaluable tool in the field of pathology for diagnosing diseases (e.g., cancer, infections), understanding cellular functions, and developing targeted therapies. The key products commonly used in IHC are primary & secondary antibodies, detection kits, blocking reagents, antigen retrieval solutions, mounting media, control tissues, and slide stainers & imaging systems. IHC has a wide range of applications across various fields of research, diagnostics, and drug development. Get Detailed Insights on Immunohistochemistry (IHC) Market Report with a Sample PDF @ https://meditechinsights.com/immunohistochemistry-market/request-sample/ Launch of novel IHC reagents and platforms to fuel its demand Continuous advances in IHC have enabled to develop efficient and easy-to-use tests with advanced features such as AI-powered solutions, increased reproducibility, high throughput capability, ability to identify patients for targeted therapies, quick turnaround time, and improved accuracy. Such advancements tend to provide competitive edge to manufacturers and therefore, major players are continuously focusing on new product development to strengthen their positions in this high growth market. Some of the technological advancements are listed below: In October 2023, Bio SB, Inc., a cancer diagnostics company launched its new robotic and automated platform to process cancer biopsies using IHC. Featuring its patented sweeping cap gap reagent motion technology, the platform helps to predict how to treat cancer using personalized medicine In September 2023, Cell Signaling Technology (CST), a provider of antibodies, kits, and services launched its SignalStar Multiplex IHC technology, a new tool for spatial biology research. The new tool uses mid-plex and high-throughput IHC assays, to amplify the antibody signals and detect targets with low expression levels In March 2023, Aptamer Group launched a new reagent, Optimer-Fc, an antibody alternative, for use in automated IHC workflows. This reagent enables life science researchers to pursue novel and existing disease biomarkers, offering increased accuracy in detection Increasing partnerships to develop novel technologies to boost adoption High growth of the IHC market has attracted a lot of interest among market players to undertake research partnerships for the development of novel technologies as well as increase the applications further enhancing the adoption of this technology for research as well as clinical applications. Some of the these are listed below: In August 2023, Visiopharm and Boston Cell Standards entered into a partnership to co-develop IHC technology by integrating IHC calibration standards with AI-driven image analysis software for quality assurance. This development is intended to meet regulatory guidelines and protocols by diagnostic laboratories including reference standards, assay calibration, and quantitative controls In June 2023, Mindpeak, a provider of AI for pathology, partnered with Proscia, a provider of digital and computational pathology solutions to broaden access to advanced cancer diagnostic technologies by integrating CE-IVD algorithms for IHC quantification with Proscia’s CE-IVDR Concentriq Dx software platform, further delivering tightly integrated AI-powered workflows for more efficient, informed, and reproducible clinical decisions In January 2023, Agilent Technologies, Inc. entered into a partnership with Akoya Biosciences, Inc. for the development and commercialization of multiplex-IHC diagnostic solutions for tissue analysis. This partnership is aimed at integrating its Dako Omnis (autostaining instrument) with Akoya’s PhenoImager HT (imaging platform) to develop end-to-end commercial solution, including reagents, staining, imaging, and analysis Irrespective of the challenges such as stringent regulatory requirements, lack of standardization, presence of alternative technologies, and high cost of instruments; the global IHC market has high potential to grow at a steady rate and is expected to gain further momentum in the coming years due to a strong emphasis on developing novel technologies such as AI integration & multiplexed IHC, ongoing trend of laboratory automation, high growth of the companion diagnostics market, and rising research activities, among others. About Medi-Tech Insights Medi-Tech Insights is a healthcare-focused business research & insights firm. Our clients include Fortune 500 companies, blue-chip investors & hyper-growth start-ups. We have successfully completed 100+ projects in Digital Health, Healthcare IT, Medical Technology, Medical Devices & Pharma Services. Contact: Ruta Halde Associate, Medi-Tech Insights +32 498 86 80 79 info@meditechinsights.com

Tag: Immunohistochemistry (IHC) Market

Immunohistochemistry (IHC) Market Projected to Grow At A CAGR of 8-9% from 2024 to 2029, Explore Detailed Insights

The US Branded Generics Market was valued at $19.1 billion in 2022 and is expected to increase at a pace of around 9-10% by 2027.

Global Lipid Nanoparticles CDMO Market is poised to witness a healthy and a double-digit growth rate by 2027

Global Digital Diabetes Management Market: Forecasting Robust 20% Growth by 2026

Global Mechanical Thrombectomy Devices Market Sets Sights on a Promising Future: 6% Growth Expected in the Next 5 Years

Global cell-based assays market is set for exponential growth, with a CAGR of 8-10% by 2029

The Transplantation market encompassing organ and tissue transplantation is expected to grow at a CAGR of 9-10% by 2029

Immunohistochemistry (IHC) Market Projected to Grow At A CAGR of 8-9% from 2024 to 2029, Explore Detailed Insights

Global High Potency Active Pharmaceutical Ingredients (HPAPI) market is poised to grow at a high CAGR of 9% in the next 5 years.

The Medical Holography Market is estimated to develop at a CAGR of 29% by 2029.

Proteomics market growth is anticipated to reach 12–15% CAGR between 2024 and 2029.